B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 157.7 DKK 0.86% Market Closed
Market Cap: 12.4B DKK

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 190.05 DKK. Compared to the current market price of 157.7 DKK, Bavarian Nordic A/S is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
190.05 DKK
Undervaluation 17%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
83
vs Industry
76
Median 3Y
2.7
Median 5Y
5.7
Industry
7
Forward
1.9
vs History
46
vs Industry
9
Median 3Y
12.2
Median 5Y
12.2
Industry
21.8
Forward
9
vs History
62
vs Industry
14
Median 3Y
7.5
Median 5Y
8.2
Industry
19.3
vs History
8
vs Industry
3
Median 3Y
-8.1
Median 5Y
-8.7
Industry
22.7
vs History
96
vs Industry
58
Median 3Y
1.4
Median 5Y
1.9
Industry
2.4
vs History
87
vs Industry
68
Median 3Y
2.5
Median 5Y
5.4
Industry
7.3
Forward
1.6
vs History
75
vs Industry
62
Median 3Y
4.7
Median 5Y
12.4
Industry
8.8
vs History
59
vs Industry
13
Median 3Y
6.6
Median 5Y
8.4
Industry
4
Forward
4.6
vs History
41
vs Industry
10
Median 3Y
8.5
Median 5Y
8.5
Industry
3.7
Forward
6.4
vs History
62
vs Industry
15
Median 3Y
6.4
Median 5Y
7.1
Industry
4.5
vs History
14
vs Industry
3
Median 3Y
-7.8
Median 5Y
-10.4
Industry
3.2
vs History
91
vs Industry
57
Median 3Y
1.2
Median 5Y
1.5
Industry
4.5

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
12.3B DKK 2.2 12.5 6.4 10.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 020 097 -166 445.3 -202 117.7 -199 811.3
US
Abbvie Inc
NYSE:ABBV
344.2B USD 6.1 81.2 16 24.2
US
Amgen Inc
NASDAQ:AMGN
154.2B USD 4.6 37.7 15.5 27.4
US
Gilead Sciences Inc
NASDAQ:GILD
130.2B USD 4.5 271.3 10.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.6B USD 11.8 -241.8 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 011.7 -513.3 -559 -544.1
AU
CSL Ltd
ASX:CSL
121.6B AUD 5.1 28.4 17.5 21.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65B USD 4.6 14.7 9.2 10.2
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.4 -64 -57.7
NL
argenx SE
XBRU:ARGX
34.6B EUR 17.9 47.1 -2 663.7 -1 785.9
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 183 835
2.2
0%
N/A
FR
Pharnext SCA
OTC:PNEXF
35 020 097
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.8
10%
1.2
US
E
Epizyme Inc
F:EPE
2 011.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
39%
0.5
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 70.4
12.5
0%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 445.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.2
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
37.7
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
271.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28.4
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A
NL
argenx SE
XBRU:ARGX
47.1
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 14.5
6.4
6%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 117.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
18%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 663.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 19.4
10.9
10%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 811.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.2
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
27.4
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -544.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 785.9 N/A N/A